APD334-003 (S1P1 receptor antagonist) in UC

Print

Details of Research

Contact: Shelley Mikolainis, Research Coordinator
416-586-4800 ext 4989
smikolainis@mtsinai.on.ca

Primary Investigator: Dr. Hillary Steinhart

Enrolment: Ongoing

Expectations: oral once daily, (1 mg, 2 mg or placebo), may be eligible open label study

Eligibility


Exclusions
: previous treatment with more than 2 biologic agents, history of retinal macular edema